A trial looking at doxorubicin with either docetaxel or cyclophosphamide for early, locally advanced or inflammatory breast cancer

Cancer type:

Breast cancer

Status:

Results

Phase:

Phase 3

This trial was comparing different combinations of chemotherapy before surgery for breast cancer.

Doctors often give chemotherapy after surgery for early stage breast cancer because it reduces the risk of the cancer coming back. If the tumour in the breast is large, you may have chemotherapy to reduce the size of the tumour before surgery (neoadjuvant treatment Open a glossary item).

In this trial, the researchers were comparing a combination of doxorubicin and docetaxel with doxorubicin and cyclophosphamide for people who need chemotherapy before surgery.

The aim of this trial was to see which combination worked best as neoadjuvant treatment for women who had a tumour that was 3cm or more in size, or who had locally advanced or inflammatory breast cancer.

Summary of results

The trial team found that both combinations worked about as well as each other.

The trial recruited 363 women. They had up to 6 cycles of treatment and then had surgery. Half the women had doxorubicin and docetaxel, the other half had doxorubicin and cyclophosphamide.

With the combination of doxorubicin and cyclophosphamide, the cancer responded in 61 out of every 100 women treated (61%). In 17 out of every 100 women (17%) who had this combination, all signs of cancer had disappeared when their breast was examined.

With doxorubicin and docetaxel, the cancer responded in 70 out of every 100 women treated (70%). And with this combination, breast examination showed that all signs of cancer had disappeared in 20 out of every 100 women (20%).

After nearly 3 years of follow up, cancer had come back in 55 of the women who had doxorubicin and cyclophosphamide. It had come back in 45 of the women who had doxorubicin and docetaxel.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor J Evans

Supported by

The Anglo-Celtic Cooperative Oncology Group

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 36

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Caroline took part in a clinical trial for breast cancer

“I had treatment last year and I want to give something back.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think